Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
My Bing
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
Trending on Bing
House passes antisemitism bill
Linked to E. coli outbreak
Holds interest rates steady
Police kill armed student
AZ Senate repeals ban
Deepest blue hole in the world
4.1 quake hits near Corona
Cancels $6.1B student loans
55 injured after collision
Signs bail fund restrictions
FTC targets ‘junk’ patents
Endangered list removal
Proposes Johnson's ouster
US private payrolls rose
Repeal anti-LGBTQ policies
Judges block La. map
Maverick vehicles recalled
Wins NY special election
Bitcoin falls below $60K
Appears in New York court
VP Harris visits Florida
Baby sea turtles rescued
Saturn's moon habitability
57-million-yr-old turtle fossils
FTC to rule on $60B deal
US author Paul Auster dies
Eta Aquarid meteor shower
Protest crackdown arrests
$10B+ renewable energy deal
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Weight Loss Drug, Sleep Apnea
Weight Loss Drug Zepbound May Help Sleep Apnea, Study Finds
The U.S. Food and Drug Administration (FDA) approved Zepbound for the treatment of obesity in November 2023. Some prescribe the weekly injection off-label to those with sleep apnea, driving Eli Lilly to test the drug for obstructive sleep apnea back in June 2022. Over 400 participants were enrolled in the trial.
Weight-loss drug linked to sleep apnea reduction: Research
The weight-loss drug Zepbound was linked to a reduction in obstructive sleep apnea (OSA), according to new research. Pharmaceutical manufacturer Eli Lilly on Wednesday said injections of its
Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says
Eli Lilly’s weight loss drug Zepbound was found to reduce obstructive sleep apnea in adults with obesity, the drugmaker said in a release Wednesday.
Eli Lilly's weight loss drug Zepbound could help treat sleep apnea — paving a way to Medicare coverage
Eli Lilly announced today that the drug behind Zepbound was found to help alleviate sleep apnea in patients with obesity in late-stage clinical trials. The medication, tirzepatide, is sold by the company in the United States as Mounjaro for diabetes and Zepbound for weight loss.
Eli Lilly’s weight-loss drug Zepbound might help cure your sleep apnea
Eli Lilly and Company announced promising results for its weight loss drug Zepbound, indicating its potential as a treatment for sleep apnea.
Weight loss drug Zepbound ‘significantly reduced’ sleep apnea in trials
Drugmaker Eli Lilly said Wednesday its weight loss drug Zepbound was shown to “significantly reduce” sleep apnea severity in adults in clinical trials.
Weight-loss drug Zepbound reduces sleep apnea, study shows
Zepbound, one of the wildly popular weight-loss drugs that millions of Americans now take, eased sleep apnea in obese adults in two company trials, drug maker Eli Lilly announced Wednesday.
Zepbound Weight Loss Drug May Help Relieve Sleep Apnea Symptoms
In a new study, people with obesity who received weight-loss drug Zepbound saw a greater average reduction in sleep apnea events over the course of a year, compared to people who received a non-acting placebo.
Weight loss drug Zepbound is also effective for sleep apnea, study finds
Weight loss drugs like Ozempic and Mounjaro have gained great traction in recent months, and now drugmakers have found another benefit of the popular medic
Weight loss drug Zepbound may help with sleep apnea
Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said recently.
Why GLP-1 Drugs May Improve Sleep Apnea
Key Takeaways Clinical trials of Eli Lilly's tirzepatide have demonstrated that participants on the medication experienced a significant reduction in obstructive sleep apnea symptoms.Excess weight around the throat and airways can contribute to obstructive sleep apnea by causing tissues to collapse and block the airway.
Medical News Today
8d
Zepbound and Mounjaro improve sleep apnea symptoms, Eli Lilly trial shows
A new clinical trial from drugmaker Eli Lilly shows that Zepbound and Mounjaro reduced obstructive sleep apnea symptoms.
Everyday Health on MSN
8d
Zepbound and Mounjaro Might Help Reduce Obstructive Sleep Apnea Symptoms
Tirzepatide, the active ingredient in Mounjaro and Zepbound, reduced sleep apnea symptoms in people with obesity, whether or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback